Cargando…

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

BACKGROUND: Aztreonam lysine for inhalation (AZLI) is an inhaled antibiotic used to treat chronic Pseudomonas aeruginosa infection in CF. AZLI improves lung function and quality of life, and reduces exacerbations-improvements attributed to its antipseudomonal activity. Given the extremely high aztre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heirali, Alya A., Workentine, Matthew L., Acosta, Nicole, Poonja, Ali, Storey, Douglas G., Somayaji, Ranjani, Rabin, Harvey R., Whelan, Fiona J., Surette, Michael G., Parkins, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420135/ https://www.ncbi.nlm.nih.gov/pubmed/28476135 http://dx.doi.org/10.1186/s40168-017-0265-7

Ejemplares similares

Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities
por: Acosta, Nicole, et al.
Publicado: (2020)

Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis
por: Whelan, Fiona J., et al.
Publicado: (2017)

Azithromycin and the microbiota of cystic fibrosis sputum
por: Acosta, Nicole, et al.
Publicado: (2021)

A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome
por: Woo, T. E., et al.
Publicado: (2019)

1481. Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients
por: Edwards, Brett, et al.
Publicado: (2018)

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response
por: Lam, John C, et al.
Publicado: (2015)

Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections
por: Heirali, Alya, et al.
Publicado: (2016)

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis
por: Skolnik, Kate, et al.
Publicado: (2015)

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa
por: Somayaji, R., et al.
Publicado: (2015)

Stenotrophomonas maltophilia natural history and evolution in the airways of adults with cystic fibrosis
por: Izydorczyk, Conrad, et al.
Publicado: (2023)

Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis
por: Woo, Taylor E., et al.
Publicado: (2018)

The natural history and genetic diversity of Haemophilus influenzae infecting the airways of adults with cystic fibrosis
por: Izydorczyk, Conrad, et al.
Publicado: (2022)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Phenotypic Heterogeneity of Pseudomonas aeruginosa Populations in a Cystic Fibrosis Patient
por: Workentine, Matthew L., et al.
Publicado: (2013)

Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission
por: Izydorczyk, Conrad, et al.
Publicado: (2020)

Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation
por: Thornton, Christina S, et al.
Publicado: (2022)

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
por: Daddario, Martha K, et al.
Publicado: (2010)

Culture Enriched Molecular Profiling of the Cystic Fibrosis Airway Microbiome
por: Sibley, Christopher D., et al.
Publicado: (2011)

Clinical Outcomes Associated With Escherichia coli Infections in Adults With Cystic Fibrosis: A Cohort Study
por: Edwards, B D, et al.
Publicado: (2019)

65 Clinical outcomes of chronic “Prairie Epidemic Strain” Pseudomonas aeruginosa infection in adults with cystic fibrosis
por: Somayaji, R., et al.
Publicado: (2015)

Draft Genome Sequence of Burkholderia dolosa PC543 Isolated from Cystic Fibrosis Airways
por: Workentine, Matthew L., et al.
Publicado: (2014)

Role of Inhalational Aztreonam Lysine in Lower Airway Infections in Cystic Fibrosis: An Updated Literature Review
por: Zeb, Mehwish, et al.
Publicado: (2022)

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review
por: Kirkby, Stephen, et al.
Publicado: (2011)

Phenotypic and Genotypic Comparison of Epidemic and Non-Epidemic Strains of Pseudomonas aeruginosa from Individuals with Cystic Fibrosis
por: Duong, Jessica, et al.
Publicado: (2015)

Metastatic Bladder Cancer Presenting with Persistent Hematuria in Young Man with Cystic Fibrosis
por: Patel, Premal, et al.
Publicado: (2013)

Discerning the Complexity of Community Interactions Using a Drosophila Model of Polymicrobial Infections
por: Sibley, Christopher D., et al.
Publicado: (2008)

Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation
por: Keating, Claire L., et al.
Publicado: (2021)

Incidence and Outcomes of Endophthalmitis Associated Hospitalizations in Children Aged ≤ 20 Years: A Population-Based Cohort Study
por: Edwards, Brett, et al.
Publicado: (2017)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Principles and Terminology for Host–Microbiome–Drug Interactions
por: Heirali, Alya, et al.
Publicado: (2023)

Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study
por: Thornton, Christina S, et al.
Publicado: (2015)

Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis
por: Thornton, Christina S., et al.
Publicado: (2022)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
por: Skolnik, Kate, et al.
Publicado: (2017)

Lung clearance index to detect the efficacy of Aztreonam lysine inhalation in patients with cystic fibrosis and near normal spirometry – A single-centre feasibility study
por: Ellemunter, Helmut, et al.
Publicado: (2019)

Eradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis
por: Iglesias, A., et al.
Publicado: (2014)

1079. When Does a Trans-Esophageal Echocardiogram (TEE) Change Management of Staphylococcus aureus Bacteremia (SAB)?
por: Lam, John, et al.
Publicado: (2018)

Effects of Levofloxacin, Aztreonam, and Colistin on Enzyme Synthesis by P. aeruginosa Isolated from Cystic Fibrosis Patients
por: Pani, Arianna, et al.
Publicado: (2022)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

A comprehensive evaluation of the sl1p pipeline for 16S rRNA gene sequencing analysis
por: Whelan, Fiona J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o5uhhrje0i7rsc61su12ou4be2